查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087853

臉部注射劑市場：2026-2032年全球市場預測（按產品類型、治療類型、年齡層、效果持續時間、技術和最終用戶分類）

Facial Injectables Market by Product Type, Procedure Type, Age Group, Duration of Effect, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，臉部注射劑市場規模將達到 231.4 億美元，複合年成長率為 9.71%。

主要市場統計數據
基準年 2025 120.9億美元
預計年份：2026年 130.2億美元
預測年份：2032年 231.4億美元
複合年成長率 (%) 9.71%

臉部注射產品，包括肉毒桿菌毒素製劑、透明質酸填充劑、膠原蛋白促效劑、烴基磷灰石鈣和其他軟組織填充產品，仍是醫療美容領域最強勁的細分市場之一。推動市場需求成長的因素包括：人們對微創治療的偏好、更短的恢復期、社交媒體上日益增強的美容意識，以及臉部回春、輪廓塑造和修復性美容治療應用範圍的不斷擴大。

根據美國整形外科醫師協會（ASPS）的數據，2023年，A型肉毒桿菌毒素和透明質酸填充劑是美國非手術美容計畫中最大的兩大類，分別進行了約950萬例和530萬例。如此龐大的手術量清楚地表明，醫療保健專業人員、製造商和經銷商為何在遵守醫療和廣告法規的同時，優先考慮差異化配方、安全培訓、數位諮詢工具和本地化服務策略。

一項革命性的變革，將徹底改變臉部注射的使用方式。

臉部注射治療領域正從以注射量為主導的模式轉向以精準治療為核心的概念。患者越來越傾向於尋求個人化的治療方案，以達到更自然的效果，並結合預防性治療、神經調節劑、皮膚填充劑、皮膚強化劑、能量設備以及再生美容療法。這凸顯了操作者技能、解剖學注射訓練、病患篩選、無菌操作技術以及完善的安全標準的重要性日益凸顯。

人工智慧（AI）的累積影響

人工智慧 (AI) 正透過影像分析、臉部映射、治療模擬、自動病患登記、不利事件監測和診所工作流程最佳化等方式，開始影響臉部注射治療。在合格醫療專業人員的監督下使用時，AI 工具有助於規範照片記錄，並實現對對稱性、容量流失、動態皺紋、皮膚品質和治療史等進行更一致的評估。

主要臉部填充劑市場的關鍵區域趨勢

在亞太地區，受可支配收入成長、都市區診所發展以及消費者對美容創新日益濃厚的興趣推動，中國、日本、韓國、印度和澳洲等國的美容醫療服務正在不斷普及並蓬勃發展。韓國憑藉其先進的治療文化和醫療旅遊，持續引領臉部美學的發展；而日本則注重精緻自然的美容效果。中國在國家藥品監督管理局的監管下開展美容醫療服務；印度主要城市的私立診所需求不斷成長；澳洲則在美容醫療實踐中保持著高標準的職業操守。

臉部填充劑擴散情況的主要群體分析

在東協，由於醫療旅遊、中產階級消費成長以及新加坡、泰國、馬來西亞、印尼和越南等國診所密度的增加，需求正在擴大。該地區的商業機會與從業人員培訓、消費者教育以及正品供應密切相關。海灣合作理事會（GCC）國家是高價值市場，高階注射、奢華健康、皮膚科主導的護理以及專業美容中心蓬勃發展，這得益於富裕的消費者、完善的醫療旅遊基礎設施以及對精細臉部回春的強勁需求。

優先面部注射市場主要國家的洞察

美國在非手術注射美容計畫數量方面領先，這得益於其強大的醫療服務網路、消費者對神經調節劑和填充劑的熟悉程度，以及美國食品藥物管理局（FDA）的積極監管。同時，加拿大在規範的醫療體系下穩步發展，都市區美容診所的需求也十分強勁。墨西哥和巴西受益於美容文化、醫療旅遊以及私營部門提供的服務，但產品品質保證、合法分銷和從業人員認證對於永續成長仍然至關重要。

面部注射行業領導者使用的實用建議

行業領導企業應優先考慮基於證據的差異化、從業人員教育、不利事件應對準備以及透明的產品認證。對於臉部注射而言，手術效果很大程度上取決於技術、解剖學知識、嚴格遵守劑量以及患者選擇。因此，投資系統培訓、併發症管理方案、無菌技術和繼續醫學教育的品牌和診所，能夠與醫療保健提供者、監管機構和患者建立更牢固的信任關係。

調查方法

本執行摘要基於二手研究框架，採用公開檢驗的資訊來源，包括專業學會的統計數據、監管指南、同行評審的科學文獻、臨床教育材料以及國家衛生部門的資訊。資訊來源包括美國整形外科醫師協會、國際美容整形外科學會、美國食品藥物管理局(FDA) 的指南、歐洲法規結構以及國家層面的美容醫學安全標準。

結論

臉部注射領域正邁入一個更成熟的階段，其特點是注重個人化、安全性、臨床證據以及利用科技手段提升患者參與度。儘管注射療法能夠以最小的恢復期帶來顯著的美容效果，因此市場需求依然強勁，但長期療效取決於合格的醫師、可靠的產品、合適的患者選擇以及切實可行的治療方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 臉部注射器市場：依產品類型分類

  • 肉毒桿菌毒素
    • 阿伏肉毒素A
    • 肉毒桿菌A
    • 肉毒桿菌A
  • 皮膚填充劑
    • 烴基磷灰石鈣
    • 膠原蛋白
    • 玻尿酸
    • 聚左旋乳酸

第8章 臉部注射器市場：依治療類型分類

  • 美容和美學治療
  • 治療

第9章 臉部注射劑市場：依年齡層別分類

  • 30-50歲
  • 超過50歲
  • 30歲以下

第10章：臉部注射劑市場：依效果持續時間分類

  • 3-6個月
  • 6-18個月

第11章 臉部注射器市場：依技術分類

  • 調變器
  • 填充劑
  • 生物刺激器
  • 用於再生醫學的注射劑

第12章 臉部注射器市場：依最終使用者分類

  • 皮膚科診所
  • 醫院
  • 醫療水療中心
  • 整形外科診所

第13章 臉部注射器市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 臉部注射器市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 臉部注射器市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Anika Therapeutics, Inc.
  • BioPlus Co., Ltd.
  • Bioxis Pharmaceuticals
  • Bloomage BIoTechnology Corporation Limited
  • Croma-Pharma GmbH
  • Daewoong Pharmaceutical Co., Ltd.
  • Evolus, Inc.
  • Galderma SA
  • Huadong Medicine Co., Ltd.
  • Huons Global Co., Ltd.
  • Ipsen SA
  • Laboratoires Expanscience SA
  • LG Chem Ltd.
  • Medytox, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Prollenium Medical Technologies Inc.
  • Revance Therapeutics, Inc.
  • SciVision BIoTech Inc.
  • Sinclair Pharma Limited
  • Suneva Medical, Inc.
  • Taro Pharmaceutical Industries Ltd.
  • Teoxane SA
Product Code: MRR-0355054AC48C

The Facial Injectables Market is projected to grow by USD 23.14 billion at a CAGR of 9.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.09 billion
Estimated Year [2026] USD 13.02 billion
Forecast Year [2032] USD 23.14 billion
CAGR (%) 9.71%

Facial injectables, including botulinum toxin products, hyaluronic acid fillers, collagen stimulators, calcium hydroxylapatite, and other soft-tissue augmentation products, remain one of the most resilient segments in medical aesthetics. Demand is supported by minimally invasive treatment preferences, shorter recovery time, social media-driven beauty awareness, and expanding use across facial rejuvenation, contouring, and restorative aesthetics.

Data from the American Society of Plastic Surgeons shows that botulinum toxin type A and hyaluronic acid fillers were the two largest nonsurgical cosmetic procedure categories in the United States in 2023, with approximately 9.5 million and 5.3 million procedures, respectively. This procedure scale underscores why providers, manufacturers, and distributors are prioritizing differentiated formulations, safety training, digital consultation tools, and region-specific access strategies while maintaining compliance with medical and advertising regulations.

Transformative Shifts Reshaping Facial Injectables

The facial injectables landscape is shifting from volume-led adoption to precision-led care. Patients are increasingly seeking natural-looking outcomes, preventive treatments, and personalized plans that combine neuromodulators, dermal fillers, skin boosters, energy-based devices, and regenerative aesthetic protocols. This has increased the importance of practitioner skill, anatomy-based injection training, patient selection, sterile technique, and documented safety standards.

Regulatory scrutiny is also rising. The U.S. FDA continues to emphasize that dermal fillers should be administered by licensed health care professionals and has warned against unapproved needle-free injection devices for fillers. In Europe, the Medical Device Regulation has strengthened clinical evidence and post-market surveillance expectations for aesthetic medical devices. These shifts favor stakeholders with robust clinical data, traceable supply chains, physician education programs, adverse event reporting systems, and compliant promotional practices.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence facial injectables through imaging, facial mapping, treatment simulation, patient intake automation, adverse event monitoring, and clinic workflow optimization. AI-enabled tools can help standardize photographic documentation and support more consistent assessment of symmetry, volume loss, dynamic wrinkles, skin quality, and treatment history when used under qualified medical supervision.

The cumulative impact of AI is expected to be operational and decision-support oriented rather than fully autonomous. In a regulated medical aesthetics environment, AI should augment, not replace, clinical judgment, informed consent, anatomical expertise, aseptic practice, and complication management. Stakeholders that validate algorithms, protect patient data, reduce bias in image analysis, and integrate AI with compliant practice management systems are positioned to improve consultation quality, follow-up care, and patient retention.

Key Regional Insights Across Major Facial Injectables Markets

Asia-Pacific is gaining momentum as China, Japan, South Korea, India, and Australia expand access to aesthetic medicine, supported by rising disposable income, urban clinic development, and high consumer engagement with beauty innovation. South Korea continues to influence facial aesthetics through advanced procedural culture and medical tourism, Japan emphasizes subtle and natural outcomes, China operates under National Medical Products Administration oversight, India is expanding demand in metropolitan private clinics, and Australia maintains strong professional standards for cosmetic medical practice.

North America remains a benchmark region due to high procedure volumes, established injector networks, FDA-regulated products, and mature patient awareness, with the United States representing a major reference point for neuromodulator and dermal filler adoption. Latin America benefits from strong medical aesthetics culture in Brazil and Mexico, where beauty-driven demand and cross-border care support injectable procedures, while Europe is shaped by clinician-led demand, cross-border aesthetic travel, and stricter EU Medical Device Regulation requirements. The Middle East, particularly Gulf markets, is developing premium aesthetic hubs supported by affluent consumers and specialist clinics, while Africa shows early-stage growth concentrated in urban private practices where product authenticity, injector training, affordability, and regulated distribution remain critical.

Key Group Insights for Facial Injectables Adoption

ASEAN demand is expanding through medical tourism, growing middle-class spending, and rising clinic density in Singapore, Thailand, Malaysia, Indonesia, and Vietnam, with regional opportunities tied to practitioner training, consumer education, and access to authentic products. The GCC is a high-value environment where premium injectables, luxury wellness, dermatology-led care, and specialist aesthetic centers are supported by affluent consumers, medical tourism infrastructure, and strong demand for discreet facial rejuvenation.

The European Union is defined by harmonized regulatory standards, heightened post-market surveillance expectations, and strong demand in Germany, France, Italy, and Spain, making clinical documentation and compliance central to injectable product strategies. BRICS countries offer broad demographic scale and long-term procedural opportunity, but require localized pricing, regulatory navigation, distribution control, and counterfeit-risk mitigation. G7 markets remain innovation leaders with high procedure penetration, established provider education, and sophisticated safety expectations, while NATO economies overlap with many advanced, compliance-driven injectable markets where procurement, training, and medical governance strongly influence adoption.

Key Country Insights for Priority Facial Injectables Markets

The United States leads in documented nonsurgical injectable procedure volume, supported by strong provider networks, consumer familiarity with neuromodulators and fillers, and active FDA oversight, while Canada shows stable adoption within a regulated medical framework and strong demand in urban aesthetic clinics. Mexico and Brazil combine aesthetic culture with medical tourism and private-sector procedural access, although product quality assurance, authorized distribution, and injector credentialing remain central to sustainable growth.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature facial injectables markets with growing emphasis on safety, training, natural outcomes, and post-treatment follow-up, while Russia remains influenced by import dynamics, regulatory access, and local supply constraints. China, India, Japan, Australia, and South Korea represent diverse Asia-Pacific opportunities, with South Korea driving aesthetic innovation and procedural tourism, Japan emphasizing subtle rejuvenation, China scaling under NMPA oversight, India expanding urban demand through dermatology and cosmetic clinics, and Australia maintaining strong practitioner standards and public scrutiny around cosmetic medical safety.

Actionable Recommendations for Facial Injectables Leaders

Industry leaders should prioritize evidence-backed differentiation, injector education, adverse event readiness, and transparent product authentication. In facial injectables, outcomes depend heavily on technique, anatomy knowledge, dosing discipline, and patient selection; therefore, brands and clinics that invest in structured training, complication protocols, sterile practice, and continuing medical education can build stronger trust with providers, regulators, and patients.

Commercial strategies should also combine premium positioning with digital enablement. Manufacturers, distributors, and clinics should use compliant AI tools for consultation support, improve inventory traceability, localize messaging by region, strengthen authorized-channel verification, and develop patient retention models based on maintenance planning, aftercare, and realistic expectations rather than one-time treatment acquisition.

Research Methodology

This executive summary is grounded in a secondary research framework using publicly available, verifiable sources, including professional society statistics, regulatory agency guidance, peer-reviewed scientific literature, clinical education materials, and national health authority information. Sources considered include the American Society of Plastic Surgeons, International Society of Aesthetic Plastic Surgery, U.S. Food and Drug Administration guidance, European regulatory frameworks, and country-level medical aesthetics safety references.

Insights were synthesized through trend triangulation across procedure volume indicators, regulatory developments, regional adoption patterns, product categories, clinical workflow changes, and documented safety considerations. The analysis avoids unverified market-size claims, market share statements, and forecasting, and instead emphasizes evidence-based indicators relevant to manufacturers, distributors, investors, aesthetic clinics, health care professionals, and policy stakeholders.

Conclusion

The facial injectables landscape is moving into a more sophisticated phase defined by personalization, safety, clinical evidence, and technology-enabled patient engagement. Demand remains strong because injectables offer visible aesthetic improvement with limited downtime, but long-term success depends on qualified administration, trusted products, appropriate patient selection, and realistic outcome planning.

The next stage of competition will reward stakeholders that align innovation with regulation, combine science with practitioner education, and address regional differences in access, culture, affordability, and safety expectations. As AI-supported consultations, premium formulations, and combination treatments advance, facial injectables will remain central to global medical aesthetics while requiring stronger governance, training, and patient protection.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Facial Injectables Market, by Product Type

  • 7.1. Botulinum Toxin
    • 7.1.1. AbobotulinumtoxinA
    • 7.1.2. IncobotulinumtoxinA
    • 7.1.3. OnabotulinumtoxinA
  • 7.2. Dermal Fillers
    • 7.2.1. Calcium Hydroxylapatite
    • 7.2.2. Collagen
    • 7.2.3. Hyaluronic Acid
    • 7.2.4. Poly-L-Lactic Acid

8. Facial Injectables Market, by Procedure Type

  • 8.1. Cosmetic / Aesthetic Procedures
  • 8.2. Therapeutic Procedures

9. Facial Injectables Market, by Age Group

  • 9.1. 30 To 50
  • 9.2. Over 50
  • 9.3. Under 30

10. Facial Injectables Market, by Duration of Effect

  • 10.1. 3-6 Months
  • 10.2. 6-18 Months

11. Facial Injectables Market, by Technology

  • 11.1. Neuromodulators
  • 11.2. Volume Fillers
  • 11.3. Biostimulators
  • 11.4. Regenerative Injectables

12. Facial Injectables Market, by End User

  • 12.1. Dermatology Clinics
  • 12.2. Hospitals
  • 12.3. Medical Spas
  • 12.4. Plastic Surgery Clinics

13. Facial Injectables Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Facial Injectables Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Facial Injectables Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Anika Therapeutics, Inc.
  • 17.3. BioPlus Co., Ltd.
  • 17.4. Bioxis Pharmaceuticals
  • 17.5. Bloomage Biotechnology Corporation Limited
  • 17.6. Croma-Pharma GmbH
  • 17.7. Daewoong Pharmaceutical Co., Ltd.
  • 17.8. Evolus, Inc.
  • 17.9. Galderma S.A.
  • 17.10. Huadong Medicine Co., Ltd.
  • 17.11. Huons Global Co., Ltd.
  • 17.12. Ipsen S.A.
  • 17.13. Laboratoires Expanscience S.A.
  • 17.14. LG Chem Ltd.
  • 17.15. Medytox, Inc.
  • 17.16. Merz Pharma GmbH & Co. KGaA
  • 17.17. Prollenium Medical Technologies Inc.
  • 17.18. Revance Therapeutics, Inc.
  • 17.19. SciVision Biotech Inc.
  • 17.20. Sinclair Pharma Limited
  • 17.21. Suneva Medical, Inc.
  • 17.22. Taro Pharmaceutical Industries Ltd.
  • 17.23. Teoxane SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL FACIAL INJECTABLES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL FACIAL INJECTABLES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL FACIAL INJECTABLES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL FACIAL INJECTABLES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL FACIAL INJECTABLES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL FACIAL INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BOTULINUM TOXIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BOTULINUM TOXIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOTULINUM TOXIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ABOBOTULINUMTOXINA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ABOBOTULINUMTOXINA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ABOBOTULINUMTOXINA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INCOBOTULINUMTOXINA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INCOBOTULINUMTOXINA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INCOBOTULINUMTOXINA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONABOTULINUMTOXINA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONABOTULINUMTOXINA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONABOTULINUMTOXINA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DERMAL FILLERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DERMAL FILLERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DERMAL FILLERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CALCIUM HYDROXYLAPATITE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CALCIUM HYDROXYLAPATITE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CALCIUM HYDROXYLAPATITE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLLAGEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLLAGEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLLAGEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYALURONIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYALURONIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYALURONIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POLY-L-LACTIC ACID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POLY-L-LACTIC ACID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POLY-L-LACTIC ACID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COSMETIC / AESTHETIC PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COSMETIC / AESTHETIC PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COSMETIC / AESTHETIC PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THERAPEUTIC PROCEDURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THERAPEUTIC PROCEDURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THERAPEUTIC PROCEDURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL 30 TO 50 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL 30 TO 50 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL 30 TO 50 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OVER 50 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OVER 50 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OVER 50 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UNDER 30 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UNDER 30 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UNDER 30 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL 3-6 MONTHS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL 3-6 MONTHS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL 3-6 MONTHS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL 6-18 MONTHS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL 6-18 MONTHS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL 6-18 MONTHS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VOLUME FILLERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VOLUME FILLERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VOLUME FILLERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOSTIMULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOSTIMULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOSTIMULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL REGENERATIVE INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL REGENERATIVE INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL REGENERATIVE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MEDICAL SPAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MEDICAL SPAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MEDICAL SPAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PLASTIC SURGERY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PLASTIC SURGERY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PLASTIC SURGERY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 148. GCC FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 149. GCC FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. GCC FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GCC FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 152. GCC FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. G7 FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. G7 FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. G7 FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 175. G7 FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. G7 FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 179. G7 FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. NATO FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 184. NATO FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 185. NATO FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. NATO FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 188. NATO FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. NATO FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL FACIAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. CANADA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. CANADA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. CANADA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 203. CANADA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 204. CANADA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. CANADA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. MEXICO FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. MEXICO FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MEXICO FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 212. MEXICO FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 213. MEXICO FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MEXICO FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. MEXICO FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. BRAZIL FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 221. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 222. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. FRANCE FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. FRANCE FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. FRANCE FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 248. FRANCE FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 249. FRANCE FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. RUSSIA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 257. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 258. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. ITALY FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. ITALY FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ITALY FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 266. ITALY FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 267. ITALY FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. SPAIN FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. SPAIN FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. SPAIN FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 275. SPAIN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 276. SPAIN FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. SPAIN FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. SPAIN FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. INDIA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 293. INDIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 294. INDIA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. INDIA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 296. INDIA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. JAPAN FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. JAPAN FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. JAPAN FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 302. JAPAN FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 303. JAPAN FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. JAPAN FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 305. JAPAN FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 311. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 312. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY BOTULINUM TOXIN, 2018-2032 (USD MILLION)
  • TABLE 320. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY DERMAL FILLERS, 2018-2032 (USD MILLION)
  • TABLE 321. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 323. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY DURATION OF EFFECT, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA FACIAL INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)